FANews
FANews
RELATED CATEGORIES
Category Healthcare
SUB CATEGORIES General  |  HIV |  Medical Schemes | 

BHF welcomes Comp Comm enquiry into pricing of cancer drugs

07 July 2017 Dr Rajesh Patel, BHF

The Board of Healthcare Funders of Southern Africa has welcomed the Competition Commission enquiry into three pharmaceutical companies regarding the pricing of oncology drugs, notably biologics.

“The BHF is of the view that since their introduction, biologics used in cancer treatment have been significantly overpriced. We also believe there should be a widening of the scope of the investigation into the pricing of biologics used in the treatment of all diseases, not just cancer - biologics are also used for treatment of systemic lupus and rheumatoid arthritis for example. The reality is that the incidence of diseases requiring biologic treatment interventions is increasing, so it is essential that the issues around cost of and access to these life-saving medicines are resolved,” explains Dr Rajesh Patel, Head: Benefit & Risk at the BHF.

“It is noteworthy that when you compare the pricing of these drugs from different manufacturers, they are all within a very narrow band, which suggests that even if there is no collusion, at the very least there is no active competition between the different pharmaceutical companies. While single exit pricing determines what pharmacies pay for medicine from suppliers or drug manufacturers, this pricing is set by the pharmaceutical company which is free determine what it charges for its medicines.

“BHF believes that South Africa is in urgent need of a scientific approach to determine how a medicine is priced, and when a medicine is priced excessively and thus unaffordable. Furthermore, the Medicines Act allows the set price in the private sector to be different to the state price for medicines as it is acceptable practice that the standardised private price of all drugs subsidises the low state price for the majority of poor or indigent South Africans. However, we have seen the subsidised cost of certain biologics to vary by more than 500% when compared with private sector costs – these price differentials are simply too enormous to overlook and demand deeper investigation,” concludes Dr Patel.

Quick Polls

QUESTION

How do you help your clients to maintain perspective when they get overwhelmed by today’s doom and gloom headlines?

ANSWER

Focus on long-term goals
Highlight global innovation
Reinforce diversification
Still figuring it out
fanews magazine
FAnews February 2025 Get the latest issue of FAnews

This month's headlines

Unseen risks: insuring against the impact of AI gone wrong
Machine vs human: finding the balance
Is embedded insurance the end of traditional broker channels?
Client aspirations take centre stage as advisers rethink retirement planning
Maximise TFSA contributions before year-end
Subscribe now